跳至主要内容
临床试验/NCT04782232
NCT04782232招募中不适用

Registry to Assess the Safety and Feasibility of the Subpulmonary Support with the Novel Venous Cannula in Patients with Failing/Absence of the Right Heart

Berlin Heart GmbH1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2021年6月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
20
试验地点
1
主要终点
Rate of mortality

研究概览

简要总结

The purpose of the study is to monitor the clinical safety and performance of the EXCOR Venous Cannula in context of an EXCOR VAD therapy to ensure continued acceptability of identified risks, to enable detecting emerging risks and to assess clinical improvement on both short- and long-term.

详细描述

The registry study has an observational, prospective, international, multi-center, non-randomized design.

The registry is planned for 42 months (3.5 years), with an enrollment period of 28 months, the follow-up of up to 12 months.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patient or his/her parent/guardian or legally authorized representative has given the consent by means of a written, signed and dated informed consent form,
  • The indications on RVAD and BVAD use of the EXCOR VAD apply,
  • Patient shall be on transplant list or at least eligible for HTx,
  • BSA (body surface area) greater than or equal to 1.2 m².

排除标准

  • Patient or his/her parents/legal guardian or legally authorized guardian has not given the consent,
  • The contraindications of EXCOR VAD apply.

结局指标

主要结局

Rate of mortality

时间窗: 30 days

Short-term mortality

Survival to heart transplantation

时间窗: up to 12 months

Long-term survival to heart transplantation

Rate of major bleeding

时间窗: 30 days

Short-term rate of major bleeding

Rate of thrombosis

时间窗: 30 days

Short-term rate of thrombosis

次要结局

  • Rate of adverse events(up to 12 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验